What is ABBV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 521.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABBV?

P/E (TTM) is 79.99 and 52-week range is $190.75 to $291.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABBV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABBV?

The company profile lists revenue (TTM) near $64.24B, net income (TTM) near $6.30B, EPS (TTM) near $3.56 when available from the market-data feed. Figures are informational and may lag live markets.

Does ABBV show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $6.78, yield near 2.37%, ex-dividend date Oct 15, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is AbbVie Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in North Chicago, Illinois, US, 1.77B shares outstanding, ISIN US00287Y1091 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

AbbVie Inc.

$ABBV

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273.

Employees

57,000

Website

www.abbvie.com/

IPO

2013-01-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US00287Y1091

Headquarters

North Chicago, Illinois, US

Shares outstanding

1.77B

NAICS sector

Manufacturing

Institutional ownership

77.31%

Browse other companiesFree AI scores and summaries for more stocks